Characterization of Amyloid Cores in Prion Domains by Sant'Anna, Ricardo et al.
1Scientific RepoRts | 6:34274 | DOI: 10.1038/srep34274
www.nature.com/scientificreports
Characterization of Amyloid Cores 
in Prion Domains
Ricardo Sant’Anna1, Maria Rosario Fernández1, Cristina Batlle1, Susanna Navarro1, 
Natalia S. de Groot1, Louise Serpell2 & Salvador Ventura1
Amyloids consist of repetitions of a specific polypeptide chain in a regular cross-β-sheet conformation. 
Amyloid propensity is largely determined by the protein sequence, the aggregation process being 
nucleated by specific and short segments. Prions are special amyloids that become self-perpetuating 
after aggregation. Prions are responsible for neuropathology in mammals, but they can also be 
functional, as in yeast prions. The conversion of these last proteins to the prion state is driven by prion 
forming domains (PFDs), which are generally large, intrinsically disordered, enriched in glutamines/
asparagines and depleted in hydrophobic residues. The self-assembly of PFDs has been thought to 
rely mostly on their particular amino acid composition, rather than on their sequence. Instead, we 
have recently proposed that specific amyloid-prone sequences within PFDs might be key to their prion 
behaviour. Here, we demonstrate experimentally the existence of these amyloid stretches inside the 
PFDs of the canonical Sup35, Swi1, Mot3 and Ure2 prions. These sequences self-assemble efficiently 
into highly ordered amyloid fibrils, that are functionally competent, being able to promote the PFD 
amyloid conversion in vitro and in vivo. Computational analyses indicate that these kind of amyloid 
stretches may act as typical nucleating signals in a number of different prion domains.
The connection between protein aggregation and human disease has fuelled the study of the molecular deter-
minants underlying this process1. It is now clear that numerous and different kinds of proteins can build highly 
ordered amyloid aggregates, similar to those associated with disorders like Alzheimer’s or Parkinson’s2. Most 
amyloids share a common fibrillar structure constituted by repetitions of a specific polypeptide chain in a regular 
β -sheet rich conformation known as cross-β , owing to its X-ray diffraction pattern3. Despite the generic nature 
of protein aggregation, it is also clear that the propensity to self-assemble into amyloid fibrils is modulated by 
the specific protein sequence4,5. Importantly, whereas the folding of globular native states relies on interactions 
involving a large majority of the protein sequence6,7, amyloid formation seems to obey the “short-stretch hypoth-
esis” in which a fibril is nucleated by specific and short sequence segments.
Prions constitute a subset of amyloids in which the aggregated state becomes self-perpetuating. The phenom-
enon is known mostly as a neuropathology in mammals, but in fungi, the aggregation of prions into amyloid-like 
conformations is exploited for beneficial purposes8–10. Despite the structural features shared between different 
amyloid aggregates, only a small set of them seems to behave as prions in natural environments. Saccharomyces 
cerevisiae prions are perhaps the best-characterized transmissible amyloids11. In these proteins, prion forma-
tion involves a structural conversion driven by relatively large, intrinsically disordered, domains enriched in 
glutamine/asparagine (Q/N) residues and, generally, depleted in hydrophobic and charged ones. Interestingly 
enough, protein domains displaying these signatures have been identified in over 250 human proteins, several of 
them linked to neurodegenerative diseases12.
The self-assembly of prion forming domains (PFDs) has been traditionally thought to ultimately rely on their 
particular amino acid composition13. According to this view, the prion-promoting residues are distributed across 
long unstructured segments from where they establish a large number of weak interactions14. The diffuse nature 
of the contacts proposed to drive prion aggregation and the consistent identification of PFDs in proteomes by 
composition-based computational methods15, has led to think that the “short-stretch hypothesis” does not apply 
to prions16. We have recently proposed that the presence and influence of specific amyloid-prone sequences 
within intrinsically disordered Q/N-rich regions are indeed important determinants of their prion behaviour17. 
These cores would differ, however, from those in disease-associated amyloids, where these regions generally com-
prise 5 to 10 residues, display a high aggregation propensity and possess a predominant hydrophobic character18. 
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Because PFDs are intrinsically disordered, in case those highly aggregating regions would be present, they would 
be exposed to solvent and ready to aggregate, precluding prion proteins to remain in their soluble and functional 
conformation under physiological conditions. Accordingly, we have suggested that in PFDs, the amyloid stretches 
should be longer and less hydrophobic, in such a way that the amyloid potential is less concentrated, making their 
aggregation sensitive to protein concentration and seeding17. They should cluster in the same sequence region 
amino acid residues with a significant amyloid propensity with residues promoting structural disorder. Q and N, 
are the residues that best balance amyloid and disorder propensity17, which would explain the over-representation 
of these particular residues in PFDs in general and in their predicted amyloid cores in particular17. We have 
shown that the implementation of this concept in our in house pWALTZ algorithm allows classifying Q/N rich 
sequences according to their prionic behaviour with better accuracy than methods relying only on composi-
tion17,19. pWALTZ aims to predict the 21 residues long sequence stretch with the average highest amyloidogenic 
potential in a Q/N rich sequential context, a length that has been shown to suffice for the formation of transmis-
sible β -folds in the case of the HET-s prion domain20 and corresponding to minimal core size allowing maximal 
discrimination between prionic and non-prionic sequences bearing similar Q/N content17.
Here, we provide experimental evidence for the existence of such Q/N rich amyloid stretches in the PFDs of 
four of the best-characterized yeast prion proteins: Sup35, Swi1, Mot3 and Ure2. pWALTZ identified potential, 
previously uncharacterized, 21 residues long amyloid stretches in the PFDs of the four proteins. The analysis of 
the corresponding peptides indicates that all them readily self-assemble into Th-T positive, β -sheet enriched, 
highly ordered amyloid fibrils displaying a typical cross-β diffraction pattern. Moreover, we demonstrate that the 
fibrils formed by the amyloid stretch of Sup35 are able to seed amyloid formation by its entire PFD with higher 
efficiency than the fibrils of the complete domain themselves. In addition, we show that infection of yeast cells 
with preformed peptide fibrils can promote the conversion of the endogenous Sup35 protein towards the prionic 
state. Finally, computational analysis indicates that mutations increasing prion propensity are often associated 
with the formation of more potent amyloid stretches in PFDs. Overall, this suggests that these relatively short 
sequences may act as important amyloid nucleating signals in prion domains.
Results
Identification of amyloid cores in Yeast Prion Domains. For the present study, we choose four of 
the best characterized prion proteins: Mot3, Sup35, Swi1 and Ure221–24. All four are yeast proteins that execute 
essential regulatory functions required for cell adaptation and survival in different conditions. Sup35 is part of the 
translation termination complex that regulates stop-codons read-through. In the soluble form, the complex binds 
the stop-codon and ends the translation; however, in the prion form [PSI+] the translation continues, increasing 
genetic variation and the chances of survival in changeable environments25,26. Swi1 is a chromatin-remodelling 
factor that regulates the expression of 6% of the yeast genome23, its self-assembly causes an expression pattern 
change that can be beneficial under certain conditions27. Mot3 is a transcription factor that regulates the expres-
sion of several hypoxic genes. Under aerobic conditions the soluble form represses, whereas under anaerobic con-
ditions the prion form [MOT3+] releases the expression of these genes24. Ure2 is a nitrogen metabolism regulator. 
In rich nitrogen conditions, the soluble form represses the use of alternative nitrogen sources, but when nitrogen 
is limiting, Ure2 self-assembles stopping this repression28. Therefore, the switch between the prion and soluble 
forms of these proteins is crucial for cell adaptation and so it is the control and regulation of this phenomenon.
Computational analyses have led us to propose that PFDs may contain specific amino acid regions capable of 
nucleating the self-assembly process17. To validate this view, we analysed the presence of potential amyloid form-
ing sequences within the PFDs of the four prions using pWALTZ17. The selected PFDs boundaries were those 
annotated in UniProt (http://www.uniprot.org) (Table 1). In all cases we could predict the presence of an amyloid 
core embedded in the corresponding PFD (Fig. 1 and Table 1). In contrast, conventional aggregation predictors 
like TANGO29, AGGRESCAN30 or PASTA31 failed to predict any significant amyloid propensity in any of the 
four pWALTZ identified sequence stretches, since they are intended to identify shorter stretches with more con-
centrated aggregation potential and the polar Q and N residues score low in these algorithms (data not shown).
Predicted PFDs amyloid cores assemble into β-sheet rich structures. The aggregation of proteins 
and peptides into amyloid fibrils usually results in the formation of intermolecular β –sheets32. We tested if the 
21 residues-long peptides corresponding to the four PFDs amyloid cores were able to convert their initially sol-
uble state into a β -sheet rich aggregated conformation using both Far-UV circular dichroism (CD) and infrared 
spectroscopy (ATR-FTIR) to monitor the changes in their secondary structure content upon incubation of the 
peptides for 2 h at 100 μ M in PBS at pH 7.4.
The comparison of the CD spectra before and after incubation (Fig. 2a) shows that, in all cases, the spec-
tra minimum shifts from 200 nm to 216 nm. This is consistent with the peptides switching from an initially 
Protein UniProt Id (PFD) Amyloid Core
pWALTZ 
score
Q/N 
(%)
Sup35 P05453 (5–135) 98-RGNYKNFNYNNNLQGYQAGFQ-118 73.99 43
Mot3 P54785 (98–295) 123-NSNNSNISASDYTVANNSTSN-143 74.27 33
Swi1 P09547 (1–323) 239-FNNSASNNGNLTSNQLISNYA-259 75.42 38
Ure2 P23202 (2–89) 20 -NIGNRNSNTTTDQSNINFEFS-40 73.65 29
Table 1. Yeast prion forming domains boundaries, predicted amyloid cores, pWALTZ scores and Q/N content.
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disordered, random coil structure, to a β -sheet enriched conformation. To further characterize this transition, 
we analyzed the amide I region of the FTIR spectrum (1700–1600 cm−1), which corresponds to the absorption 
of the carbonyl peptide bond group of the protein main chain. Deconvolution of the FTIR spectra allowed us 
to assign the individual secondary structure elements of incubated peptides and their relative contribution to 
the main absorbance signal (Fig. 2b and Table 2). In all cases, a band at ∼1625 cm−1 dominates the spectrum. 
This spectral component is usually attributed to the presence of intermolecular β –sheet structure and accounts 
for 50–60% of the area of the peptides spectrum area. Interestingly, no anti-parallel β –sheet band was detected 
(~1690 cm−1)33, suggesting thus that the β –strands in self-assembled peptides would adopt a parallel disposition. 
The other detected structural elements are associated with a disordered structure, loops and β –turns (Table 2). 
Overall, the CD and FTIR data are consistent with the assembly of the predicted PFDs amyloid cores into a highly 
enriched β –sheet structure.
Predicted PFDs amyloid cores assemble into amyloid fibrils displaying a cross-β structure. We 
used the amyloid-specific dye Thioflavin T (Th-T) to confirm that the detected β –sheet assemblies in incubated 
peptides were organized into amyloid-like superstructures. Th-T fluorescence emission is enhanced in the pres-
ence of amyloid fibrils34,35. Whereas incubation of Th-T with the initially soluble peptides did not promote any 
detectable spectral change, when incubated for 2 h, a large increase in Th-T fluorescence emission intensity was 
observed for all peptide solutions (Fig. 3).
To confirm that Th-T binding reported on amyloid-like structure, the morphological features of the peptides 
assemblies were analysed using transmission electron microscopy (TEM). Negative staining indicated that all 
peptides self-assemble forming fibrillar arrangements displaying the basic characteristics of amyloid fibrils, since 
they appear straight and unbranched, with a tendency to coalesce laterally (Fig. 4). The fibrils exhibit a diameter 
that varies from 5 to 10 nm and a length that ranges from 2 to 10 μ m.
X-ray diffraction experiments were performed on fibers containing peptide amyloid fibrils. The X-ray dif-
fraction patterns indicate that amyloid fibrils formed in every case possess the typical ‘cross-β ’-like architecture 
(Fig. 5). Specifically, a strong meridional diffraction signal is evident at 4.6–4.7 Å which arises from the repeat 
along the axis of the fibers, and represents the distance between successively hydrogen bonded β -strands which 
are aligned perpendicular to the fibril axis. Moreover, all patterns exhibit a second strong reflection along the 
equator, corresponding to a d-spacing of 8.5–9.7 Å. This structural repeat is likely to arise from the packing dis-
tance between β -sheets that are aligned parallel to the fibril axis (Table S1). The differences observed in the equa-
torial reflections indicate dissimilarities in the packing distance of each peptide and likely arise from the variable 
sizes of the side chains that are interlocked in the steric-zippers formed between the β -sheets in each case.
Sup35 PFD amyloid core seeds Sup35-NM domain amyloid formation in vitro. The assays 
reported above demonstrate that the predicted amyloid cores are able to self-assemble into amyloid fibrils. 
However, these data alone do not prove that these sequences would be able to recruit and nucleate the arrange-
ment of a full-length disordered PFD into an amyloid structure. To test this possibility, we analysed if peptide 
amyloid fibrils were able to accelerate (seed) the aggregation reaction of the entire PFD in the case of the Sup35 
protein.
We performed self and cross-seeding assays between the Sup35 peptide and the Sup35-NM prion domain (residues 
1–253). The N-terminal region comprises the PFD (residues 1–114), which is defined as the minimal region 
essential for induction and propagation of the prion state36. Acting as a linker between the N and the elongation 
factor Tu GTP binding domain of Sup35, the highly charged M region increases the solubility of the protein37 and 
imparts stability to the prion during mitosis and meiosis38. The aggregation kinetics of the peptide and Sup35-NM 
were measured by monitoring the changes in Th-T fluorescence (Fig. 6). The peptide kinetics corresponds to a 
characteristic sigmoidal aggregation reaction with a short lag phase of 20 min, reaching the stationary phase in 
Figure 1. The four proteins studied here are represented with their respective known functional domains 
(lilac). Swi1: (1) ARID/BRIGHT DNA binding domain; Sup35: (1) Elongation factor Tu GTP binding domain, 
(2) Elongation factor Tu domain 2 and (3) Elongation factor Tu C-terminal domain; Ure2: (1) Glutathione 
S-transferase N-terminal domain and (2) Glutathione S-transferase C-terminal domain. Prion domains are 
shown in green and the predicted 21 residues amyloid core inside the prion domain in red. The functional 
domains were assigned according to Pfam (http://pfam.xfam.org) and the PFD according to UniProt  
(http://uniprot.org). The exact position of the amyloid cores in the PFDs and their amino acid sequences are 
displayed in Table 1.
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less than 90 min, indicative of a fast self-assembly potential (Fig. 6A). In contrast, the aggregation of Sup35-NM 
is much slower, displaying a lag phase that lasts for 20 h, being completed only after 50 h of reaction (Fig. 6B). The 
Figure 2. PDFs amyloid cores secondary structure. The peptides secondary structure was analyzed by Far-UV 
CD (a) before (solid lines) and after incubation (dotted lines). The initial characteristic 200 nm negative peak 
corresponding to disordered structure displaces to 216 nm, indicative of a β -sheet content, upon incubation. 
The secondary structure of the incubated peptides was also analysed by ATR-FTIR (b). All of them exhibit a 
major band at ∼1625 cm−1 indicating the presence of inter-molecular β -sheets. Additional secondary structure 
components are detailed in Table 2.
Assignments Sup35 Mot3 Swi1 Ure2
Inter β -sheet (1623–1641 cm−1) 59% 49% 57% 50%
Disordered (1642–1647 cm−1) 25% 32% 16% 19%
Turns (1662–1686 cm−1) 16% — 27% 21%
β -sheet (1674–1695 cm−1) — 19% — 10%
Table 2. Assignment and area of the secondary structure components of aggregated PFDs amyloid cores in 
the amide I region of FTIR spectra.
Figure 3. Thioflavin-T binding to PDFs amyloid cores. The peptides were let to aggregate in quiescent 
solutions for 2 hours at RT and 100 μ M. Then, 10 μ L of soluble or aggregated samples were mixed with a 
solution of Th-T at 30 μ M and fluorescence was measured by exciting the samples at 450 nm and collecting their 
emission from 460 to 600 nm.
www.nature.com/scientificreports/
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addition of 2% preformed Sup35-NM seeds significantly shortens the lag phase, supporting a nuclei-dependent 
aggregation mechanism39, however the Th-T signal increases slowly achieving its maximum intensity also at 
~50 h. In contrast, the addition of 2% peptide amyloid seeds results in a fast and hyperbolic increase in Th-T 
signal that achieves its maximum intensity at 22 h without any detectable lag phase. Therefore, the conversion of 
soluble Sup35-NM into the amyloid state is at least two times faster when it is initiated by the amyloid core than 
by the complete domain itself. We also analysed whether preformed amyloid fibrils of Sup35, Ure2, Mot3 and 
Swi1 peptides were able to seed the aggregation of initially soluble Sup35 amyloid core. No cross-seeding effect 
was detected and aggregation could be only accelerated by the fibrils of the same Sup35 peptide, which abrogated 
the lag phase of the reaction (Figure S1), thus confirming sequence specificity in PFDs aggregation.
Sup35 amyloid core can promote endogenous Sup35 prion conversion in yeast. The amyloid 
fibrils formed in vitro by the Sup35-NM domain have been shown to be infectious if they enter into yeast cells. 
They induce the conversion of cells displaying the [psi−] phenotype into the prionic [PSI+] state, by seeding 
the conversion of the originally soluble native Sup35 protein into insoluble amyloid structures40. Provided that 
Sup35 PFD amyloid core fibrils sufficed to seed the aggregation of Sup35-NM in vitro, we explored if they were 
also able to promote the conversion of [psi−] yeast cells into [PSI+] ones. Purified Sup35-NM and Sup35 amyloid 
core fibrils and a vehicle solution were used to transform spheroplasts of a [psi−] yeast strain as described in the 
Material and Methods section. Subsequently, they were streaked in ¼ YPD plates. On these plates, [psi−] cells are 
of an intense red color, whereas [PSI+] cells appear white41. No [PSI+] colonies were observed for transformations 
with vehicle alone. In contrast, transformation with recombinant Sup35-NM and synthetic Sup35 PFDs amyloid 
core fibrils resulted in a 12% and 4% of [PSI+] colonies, respectively (Fig. 7), indicating that both assemblies are 
able to interact with and promote the aggregation of native endogenous Sup35 within the cell.
Figure 4. Fibrillar structure of Sup35, Mot3, Swi1 and Ure2 PFDs amyloid cores. On the upper images bars 
corresponds to 1 μ m and on the lower images to 0.5 μ m for Sup35, Mot3 and Ure2 and to 0.2 μ m for Swi1.
Figure 5. X-ray diffraction patterns collected from partially aligned fibril samples formed by the PFDs. 
Fiber axis is vertical and the arrows highlight the characteristic “cross-β” reflections. Grey 4.76 Å meridional, 
white 9–11 Å equatorial reflections.
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Mutations in amyloid cores impact prion propensity. For classical amyloids, the existence of amyloid 
cores explains why mutations that increase the aggregation potential of pre-existent sequence stretches or that 
create a novel aggregation-prone region usually result in more aggressive or early onset pathological pheno-
types42,43. By analogy, one would expect that mutations in the PFDs promoting the same effects would increase 
their prionogenicity. Indeed, we have previously observed this effect when analysing mutations of human 
hnRNPA1 and hnRNPA2 prion-like proteins associated with multisystem proteinopathy and amyotrophic lat-
eral sclerosis. The pathogenic mutations occur in the PFDs of hnRNPA1 and hnRNPA2 and map precisely in 
the 21-residues long region identified by pWALTZ, increasing in all cases the predicted amyloidogenicity of 
these sequence stretches17,44. In a recent work, Ross and co-workers have used targeted mutation to convert four 
prion-like domains having high compositional similarity to yeast prions, but devoid of prion activity, into func-
tional PFDs45. The analysis of these sequences with pWALTZ indicates that, in all cases, those mutations resulting 
in novel prionic activity have created a short sequence stretch with a higher amyloid propensity than the orig-
inal one (Table 3). These data suggest that, similar to what happens in classical amyloid stretches, if a mutation 
increases the amyloid potential of a nucleating region in a PFD it would favour sequence specific self-assembly 
and thus the population of aggregated prionogenic states.
Figure 6. Aggregation kinetics, seeding and cross-seeding reactions of Sup35 PFD amyloid core and 
Sup35-NM domain. In panel a the aggregation kinetics were carried out by incubating 100 μ M of peptide with 
30 μ M of Th-T at RT with no agitation and the fluorescence measured along time. Th-T spectra were collected 
by exciting the samples at 450 nm and collecting the emission from 460 to 600 nm. The intensity at 482 nm was 
used to monitor the extent of aggregation. In the inset are shown some representative spectra. In panel b, the 
Sup35-NM domain was incubated at 10 μ M, at RT, under agitation of 400 rpm in the absence of seeds or self-
seeded with 2% of its own fibrils or seeded with 2% of the fibrils formed by the Sup35 PFD peptide. The three 
reactions were carried out simultaneously and monitored by Th-T fluorescence. At each time point, a 10 μ L  
aliquot of each sample was mixed with 30 μ M of Th-T solution and the fluorescence spectra collected. The 
intensity at 482 nm was used as a proxy of fibril formation.
Figure 7. Conversion of non prionic [psi−] to prionic [PSI+] yeasts by transformation with Sup35 PFD 
amyloid core peptide or the complete Sup35-NM domain. Yeast cells (L1749) were transformed by incubation 
of spheroplasted cells with the transformation mixtures, containing either 10 μ g/mL pRS416 vector, or the 
pRS416 vector plus 40 μ M of Sup35 peptide fibrils, or pRS416 plus 40 μ M of NM-domain fibrils. 100 colonies 
were plated and screened for PSI positive and negative prion phenotypes in ¼ YPD plates. Representative 
positive and negative colonies are shown in this figure, together with the positive and negative control strains: 
L1749 [psi−] and L1762 [PSI+].
www.nature.com/scientificreports/
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Discussion
The formation of amyloid assemblies is connected to a significant number of human disorders1. Many research 
efforts have been directed towards understanding the factors underlying this process because they hold the 
key for the development of novel therapeutic strategies. One of the outcomes of these efforts is the so-called 
“short-stretch hypothesis”, which postulates that a short amino acid stretch could provide most of the driving 
force needed to trigger the self-assembly of a protein into an amyloid46–48. This observation has pushed the devel-
opment of over twenty different algorithms, aimed to identify these sequence stretches in disease-linked polypep-
tides49,50, whose predictions have been experimentally validated in many instances. Indeed, compounds blocking 
these regions have been shown to successfully interfere with entire protein aggregation reactions51 and conversely 
mutations that increase the amyloid propensity of these stretches usually exacerbate full-length protein deposi-
tion52. There was debate on whether the driving force of the amyloid self-assembly was the composition of these 
stretches or their sequence. By reversing and scrambling an amyloid sequence stretch we provided evidence 
that it is the sequence that governs the assembly pathway and the final amyloid conformation53. This explains 
why cross-aggregation often results in the formation of disordered aggregates and why cross-seeding reactions 
between proteins differing in their sequence are rare54.
Despite the morphological similarities between the aggregates formed by disease-linked amyloids and the 
Q/N rich functional yeast prions, at least in vitro, conventional β -aggregation and amyloid predictors fail to 
identify and score the last type of proteins. This inaccuracy owes essentially to the fact that yeast PFDs are con-
stituted by intrinsically disordered segments, which, by definition are, poor in hydrophobic residues and rich 
in polar residues. Accordingly, it has been assumed that the transition of PFDs from the soluble state to the 
amyloidogenic one arises from a bias in sequence composition favouring the establishment of a large number 
of weak interactions along the entire PDF segment55. However, we have recently proposed that prion behaviour 
also emerges from the preferential nucleation by specific and localized amyloid-prone stretches embedded in 
the wider disordered region17,19. Here we provide experimental evidence for the presence of these regions in 
the PFDs of four different yeast prions and for the ability of one of these amyloid cores to recruit the organized 
assembly of its corresponding full-length prion domain in vitro and inside the cell. This suggests that the ‘classical’ 
short-stretch nucleation model applies to prions in a similar manner as it does for the rest of amyloids. Thus, the 
main differences between these two protein types are that in prions the amyloid nucleating potency is weaker and 
less concentrated, being spread in a larger segment. This property allows the protein to remain soluble in most 
physiological conditions, but also to respond to the presence of preformed seeds that target these segments and 
promote the prion self-assembly. This short-stretch nucleation mechanism would permit a more precise control 
of self-assembly and transmissibility12 than the establishment of several weak interactions through a long disor-
dered and presumably highly flexible PFD, which will imply a high entropic cost already at the beginning of the 
reaction. In a way, the initial self-assembly step in PFDs would resemble to that mediated by short lineal motifs 
(SLIMs) residing in disordered regions, this location makes them accessible to mediate protein-protein interac-
tions roughly independently from the rest of the polypeptide56. The length of 21-residues was selected because it 
provided the best discrimination between prionic and non-prioninc Q/N rich domains17, but of course it is arbi-
trary and amyloid cores may have different lengths in different PFDs, also, we are not arguing that the identified 
amyloid cores are the only stretches that can or are necessary for prion conversion and, as it happens in classical 
amyloids, other short regions can also cooperate in the assembly reaction.
Selective pressure to reduce the burden of protein aggregation in biological organisms has minimized the 
aggregation propensities of protein sequences57, especially in intrinsically disordered protein segments where 
they are exposed to solvent58. In this context, the significant amyloid potential of the assayed sequences suggests 
that they are conserved because they serve functional purposes, being likely involved in the self-organization of 
prion macromolecular assemblies in living cells59.
Materials and Methods
Sup35-NM overexpression and purification. 20 ml of LB (100 μ g/ml Amp, 34 μ g/ml Clm) were inoc-
ulated with single colonies of BL21(DE3) pLysS cells transformed with a pET plasmid encoding for Sup35-NM 
(residues 1 to 254) and incubated overnight at 37 °C and 250 rpm. Subsequently, the culture was transferred into 
2 L LB/Amp/Clm and incubated at 37 °C and 250 rpm. Protein expression was induced at OD600 = 0.6 by addition 
Protein PFD amyloid core pWaltz Score
Puf4 HGYYNNNNNNNNNNNNNNNSN 73.8493
Puf4mut FNNNSMSSNNINVNIGNSNYN 74.2634
YL177 ––––––––––––– < 35.00
YL177mut QQQSIFYQGNVSSYISNALIH 76.1426
KC11 LQMQQLQMQQLQQQQQQQQYA 64.0547
KC11mut QQQQYAQYTNAFMINSQYVYN 82.6883
PDC2 GSSNNINDNDSSVKYLQQNTV 68.6574
PDC2mut HNNQYNSNNSNNAIFNTNNYG 77.1778
Table 3. Yeast PFDs mutants displaying increased prion propensities display a stronger amyloid core. 
Amyloid cores of wild type and mutant (mut) PFDs and their respective pWALTZ scores are shown. Mutated 
residues in the PFDs overlapping with the predicted amyloid core are shown in bold.
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of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and the culture left O/N. Cells 
were then harvested by centrifugation for 20 min at 7000 g (5296 rpm) and 4 °C (Beckman CoulterTM Avanti 
Centrifuge J-26XPI). The cell pellet was resuspended in 50 ml of denaturing buffer (20 mM Tris pH 8, 0.5 M NaCl, 
6 M guanidine, 20 mM imidazole). The suspension was sonicated for 10 min on ice (Branson Digital Sonifier). 
The lysate was centrifuged for 45 min at 48384 g and 4 °C. The supernatant was sonicated again for 10 min and 
then filtered using a 0.45 μ m low binding Millipore filter. A Nickel column HisTrap FF of 5 ml (GE Healthcare) 
was used to purify Sup35-NM carrying a C-terminal polyhistidine-tag. Sup35-NM was eluted from the column 
by one-step with 25 ml of elution buffer (20 mM Tris pH 8, 0.5 M NaCl, 6 M guanidine, 500 mM imidazole). The 
protein was further concentrated using an Amicon Ultra Centrifugal Filter (Merck KGaA).
Peptides prediction and synthesis. The sequences of the PFDs of Sup35 (P05453), Swi1 (P09547), Mot3 
(P54785) and Ure2 (P23202) proteins as annotated in UniProt were analyzed with pWALTZ17. Twenty-one 
residues-long peptides corresponding to the respective predicted amyloid cores (Table 1) were purchased from 
CASLO ApS (Scion Denmark Technical University). The peptides were weighted and dissolved in DMSO to 
obtain a stock solution of 10 mM. For Circular Dichroism analysis the stock solutions were prepared in TFE at 
10 mM to avoid the intense background noise caused by residual DMSO on the CD spectra.
Peptides Aggregation Assays. Right before each experiment the stock solutions were diluted to 100 μ M 
in PBS pH 7.4. To ensure reproducibility in the aggregation reactions, the diluted solutions were filtered 2 times 
through a low protein binding 0.22 μ m Millipore filter right before starting the measurements. The peptide con-
taining solutions were incubated at room temperature for 2 h on a ST-5 horizontal agitator (CAT Ingenieurbüro 
M. Zipperer GmbH) with shaking set to 60 rpm/min. To detect the formation of amyloid aggregates, Th-T was 
mixed with the sample to a final concentration of 30 μ M and its fluorescence measured. Samples were excited 
at 450 nm while emission was collected from 460 to 600 nm. The aggregation kinetics of the Sup35 peptide was 
followed by monitoring the change in Th-T fluorescence intensity at 482 nm along time.
Circular dichroism. Circular dichroism (CD) was used to determine the main secondary structure presented 
by soluble and aggregated peptides at the times stated on the experiments. For the soluble state, the measure-
ment was performed right after diluting the peptide stock to 20 μ M in PBS. For measurements in the aggre-
gated state, the same samples were measured again after two hours of incubation. Spectra were recorded between 
200–250 nm, at a resolution of 1 cm−1, with a 15 nm·min−1 scan rate and at room temperature in a J-810 
spectropolarimeter (Jasco Corp. Tokyo, Japan) using a quartz cell of 0.1 cm path length.
Infrared spectroscopy. Attenuated total reflectance Fourier transform infrared spectroscopy (ATR FT-IR) 
was used to determine the secondary structure content of the amyloid fibrils formed by the peptides. After the 
aggregation time (2 h), the samples were sonicated and 3 μ L placed on the ATR crystal for measurements. Samples 
were dried under a N2 stream. The experiments were carried out using a Bruker Tensor 27 FT-IR spectrometer 
(Bruker Optics) with a Golden Gate MKII ATR accessory. Each spectrum consists of 16 accumulations measured 
at a resolution of 2 cm−1 in a wavelength range between 1700 and 1600 cm−1. Infrared spectra were fitted through 
overlapping Gaussian curves, and the amplitude, mass center, bandwidth at half of the maximum amplitude, 
and area for each Gaussian function were calculated employing a nonlinear peak-fitting equation using PeakFit 
package (Systat Software, San Jose, CA).
Transmission Electron Microscopy. Aggregated samples were diluted in Milli Q water to a final concen-
tration of 10 μ M. 5 μ l of the solution were absorbed onto carbon-coated copper grids for 5 minutes and blotted 
to remove excess material. Uranyl acetate (2% w/v) was used for negative staining. Samples were dried on air for 
5 minutes. Grids were exhaustively scanned with a Hitachi H-7000 transmission electron microscope operating 
at a voltage of 75 kV.
X-Ray diffraction. The aggregates were grown in the conditions described above. The fibrils were isolated by 
centrifugation at 13,400 rpm for 30 minutes. The pellets were washed two times in Milli Q water to the discard of 
any residue of salt and the samples were concentrated to 10 mg/mL protein concentration.
Fibril samples were aligned between wax-tipped capillaries and allowed to air dry60. The partially aligned fiber 
was placed on a goniometer head and data were collected using Rigaku rotating anode source (CuKα ) and Saturn 
944 + CCD detector. The diffraction patterns were examined with Mosflm (CCP4)61 and then output as TIFs. 
Measurements of the signal positions were conducted using Clearer62.
Sup35-NM seeding assay. The stock solution of Sup35-NM domain was maintained in Guanidine 6 M to 
avoid any residual initial aggregation. At the beginning of the experiment, the protein was diluted to a final con-
centration of 10 μ M in phosphate buffer (5 mM potassium phosphate, 150 mM NaCl, pH 7.4). Reactions were car-
ried out at RT in the absence or presence of seeds. The seeds were prepared by sonicating the preformed fibrils of 
the Sup35 PFD amyloid core peptide or the fibrils of Sup35-NM for 10 min. The fibrils of the Sup35-NM domain 
were formed essentially as described63. Briefly, 10 μ M of protein were to aggregate without agitation at RT for at 
least 5 days. The amount of seeds used was 2% (v/v). At different time points, 10 μ L of each sample were mixed 
with Th-T (30 μ M) and the fluorescence emission intensity at 482 measured.
Sup35-NM domain and Sup35 peptide transformation and analysis of phenotypes. Yeast strain 
L1749 (MAT α, ade1-14, ura3-52, leu2-3,112, trp1-289, his3-200, [psi−], [PIN+]) was transformed by the method 
previously described64 with some modifications. Briefly, yeast cells were grown on YPD (1% yeast extract, 2% pep-
tone, 2% glucose) to OD600 ≈ 1.0. Yeast cells were successively washed with sterile water, 1 M sorbitol, and finally 
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resuspended in SCE buffer (1 M sorbitol, 10 mM EDTA, 10 mM DTT, 100 mM sodium citrate, pH 5.8). Cell wall 
was removed by lyticase treatment, and the resulting spheroplast cells were transformed with either the vector 
pRS416 in 2.2% DMSO (negative control), Sup35 peptide plus pRS416 in 2.2% DMSO, or Sup35-NM domain 
plus pRS416 in 2.2% DMSO. Previously to the transformation, Sup35 peptide and Sup35-NM were seeded for 
fibrillation, and sonicated for 20 min in a water-bath sonicator immediately before the transformation. Yeast 
spheroplast were washed with 1 M sorbitol and resuspended in STC buffer (1 M sorbitol, 10 mM Tris-HCl, 30 mM 
CaCl2, pH 7.5). Transformation was carried out by incubation of spheroplasted cells with the previous mixtures of 
vector, vector plus peptide or NM-domain, in the presence 200 μg/mL ssDNA and PEG solution (20% PEG8000, 
30 mM CaCl2, 10 mM Tris-HCl, pH 7.5). Yeast cells were resuspended in SOS medium (1 M sorbitol, 6.5 mM 
CaCl2, 0.25% yeast extract and 0.5% bacto peptone), and incubated at 28 °C for 30–45 min. Cells were mixed with 
top-agar (1 M sorbitol, 2.5% bacto agar) and plated on selective medium SD-Ura (0.17% yeast nitrogen base with-
out ammonium and amino acids, 0.5% ammonium sulfate, 2% glucose, 2% bacto agar, supplemented with amino 
acids but without uracil). After incubating plates at 28 °C during for 3–5 days, between 50–100 transformants 
were randomly selected, streaked onto ¼ YPD plates and incubated at 28 °C for 3 days.
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